Shanghai Securities News China Securities(News from Nian Yue, reporter Zhang Xue) On the 10th, this reporter learned from CanSino Biologics...It has been learned that CanSino Biologics (Shanghai) Co., Ltd., a subsidiary of the company, recently signed a licensing agreement with Panru Biotechnology (Tianjin) Co., Ltd. ("Panru Biotechnology"), licensing its independently developed novel three-component lipid nanoparticle delivery system (ISL-3C-LNP) to Panru Biotechnology to expand its application prospects. CanSino stated that this licensing cooperation marks another important milestone for the company in the field of mRNA delivery technology, and will bring in more than 100 million yuan in revenue in the future, including upfront payments and milestone payments.
　　According to the agreement, Panru Biotech, upon obtaining authorization, can use ISL-3C-LNP as the core LNP lipid for the global research, development, production, and commercialization of its therapeutic prostate cancer mRNA vaccine (PRBT001 injection). It is understood that PRBT001 injection possesses completely independent intellectual property rights .A novel mRNA therapeutic vaccine for prostate cancer has been developed. The core technologies of this vaccine have been incorporated into a complete global patent portfolio. It has completed comprehensive preclinical evaluation and will provide an immunotherapy option.choose.
　　Public information shows that CanSino Biologics is engaged in the research, development, production and commercialization of innovative vaccines. It currently has five major innovative vaccine platform technologies: viral vector vaccine technology, synthetic vaccine technology, protein structure design and VLP assembly technology, mRNA technology, formulation and administration technology. It has established multiple innovative vaccine products covering more than 10 indications.
　　CanSino Biologics stated that the two parties had previously collaborated in the early clinical stages of the project, and the company will subsequently leverage its mRNA technology platform to provide customized R&D and production support for the project, strengthening the external collaborative ecosystem.

https://finance.eastmoney.com/a/202511103560079460.html